Stocks Slip as Pand...
Health Care: Drugs
Opexa Therapeutics Inc. (OPXA: NASDAQ)
$1.69 0.07 | 4.32%
05/24/13 - 03:59 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | -8.93M | -5.97M | -5.47M | -1.43M |
| Operating Gains/Losses | -549.88K | 9.69K | 459.00 | 368.54K |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 0.00 | 26.24K | -26.24K | 0.00 |
| (Increase) Decrease in Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Other Current Assets | -611.61K | 0.00 | 0.00 | 0.00 |
| (Decrease) Increase In Payables | -71.41K | -13.03K | -251.76K | -19.36K |
| (Decrease) Increase In Other Current Liabilities | 83.02K | 234.92K | 186.09K | 28.59K |
| (Increase) Decrease In Other Working Capital | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Cash Items | 690.73K | 576.94K | 572.90K | 650.25K |
| Net Cash From Continuing Operations | -8.92M | -4.99M | -4.38M | -8.43K |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | -8.92M | -4.99M | -4.38M | -8.43K |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -550.39K | -296.95K | -35.35K | 0.00 |
| Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchases of Short-Term Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | -1.00M | 0.00 | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -1.55M | -296.95K | -35.35K | 0.00 |
| Issuance of Debt | 4.08M | 0.00 | 0.00 | 1.18M |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 381.31K | 8.62M | 109.64K | 5.83M |
| Repayment of Long-Term Debt | 0.00 | -35.61K | 0.00 | -62.27K |
| Repurchase of Capital Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | -509.49K | 0.00 | -67.32K | 0.00 |
| Net Cash From Financing Activities | 3.96M | 8.58M | 42.32K | 6.95M |
| Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Change in Cash & Cash Equivalents | -6.52M | 3.30M | -4.37M | 6.94M |
Portfolios with OPXA
- Portfolio NameUser Type
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- Userneed cash
- UserYaYa
- UserHealthCare Dares
- UserBENITRANS CX
- ContributorStockerblog.com Stem Cell S...
- UserSAGJ
Latest OPXA Headlines from TheStreet
- 4 Biotech Stocks Under $5 to Watch 03.15.13 | 07:03 am
- Stocks Rebound Sharply; S&P 500, Nasdaq Rise Over 1% 02.05.13 | 04:02 pm
- Investors Overreact to Opexa Finding Scant Interest for Failed Multiple Sclerosis Drug 02.05.13 | 10:02 am
- 5 Stocks Poised for Breakouts 10.12.12 | 01:10 pm
- Lessons From Biotech's Best Third Quarter Stocks 10.02.12 | 09:10 am
- Biotech Stock Mailbag: Best Stocks to Watch in '11 01.07.11 | 07:01 am
- Opexa Therapeutics Reports Third Quarter 2010 Financial Results 11.09.10 | 08:11 am
- Otix Global, Entropic: Volume Movers 09.13.10 | 02:09 pm
- Biotech Stock Mailbag: Vertex Pharma 04.09.10 | 07:04 am
- Versar, Opexa Therapeutics: Midday Volume Plays 03.30.10 | 11:03 am
Press Releases for OPXA
- Opexa Therapeutics To Present At The 6th Annual European Life Science CEO Forum - Business Wire 03.04.13 | 08:03 am
- Opexa Therapeutics, Inc. Announces Pricing Of Common Stock And Warrant Offering - Business Wire 02.07.13 | 09:02 am
- Opexa Therapeutics To Present At The 15th Annual BIO CEO & Investor Conference - Business Wire 02.07.13 | 08:02 am
- Merck Serono And Opexa Therapeutics Enter Into Option And License Agreement For Development Of Tcelna™ (imilecleucel-T) For Treatment Of Multiple Sclerosis - Business Wire 02.05.13 | 07:02 am
- Opexa Therapeutics Closes Private Note Offering - Business Wire 01.23.13 | 05:01 pm
- Opexa Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement - Business Wire 01.15.13 | 08:01 am
- Opexa Therapeutics Announces Reverse Stock Split - Business Wire 12.14.12 | 04:12 pm
- Opexa Therapeutics Reports Third Quarter 2012 Financial Results And Provides Corporate Update - Business Wire 11.14.12 | 08:11 am
- Opexa Receives Clinical Trial Approval From Health Canada For Novel T-Cell Therapy - Business Wire 11.13.12 | 08:11 am
- Opexa Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference - Business Wire 11.12.12 | 03:11 pm
Partner Headlines for OPXA
- Benzinga's Microcap Movers for Friday July 13, 2012 - Benzinga 07.14.12 | 04:07 pm
- A Busy Week for Multiple Sclerosis News - Seeking Alpha 09.26.10 | 08:09 am
